IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Y Li, X Wu, C Sheng, H Liu, H Liu, Y Tang, C Liu… - Cell, 2024 - cell.com
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …
被引用次数：3 相关文章

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Y Li, X Wu, C Sheng, H Liu, H Liu, Y Tang, C Liu… - Cell, 2024 - cell.com
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …

IGSF8 is an innate immune checkpoint and cancer immunotherapy target.

Y Li, X Wu, C Sheng, H Liu, Y Tang, C Liu, Q Ding… - Cell, 2024 - europepmc.org
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Y Li, X Wu, C Sheng, H Liu, H Liu, Y Tang, C Liu… - Cell, 2024 - pubmed.ncbi.nlm.nih.gov
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Y Li, X Wu, C Sheng, H Liu, H Liu, Y Tang, C Liu… - Cell, 2024 - Elsevier
Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

Y Li, X Wu, C Sheng, H Liu, H Liu, Y Tang, C Liu… - paper.sciencenet.cn
Antigen presentation defects in tumors are prevalent mechanisms of adaptive
immuneevasion and resistance to cancer immunotherapy, whereas how tumors evade …